Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378389 | 0.85 | HTR2C (0.57) | HTR1AHTR7HTR2C | |
| SCHEMBL2378672 | 0.83 | SMN1; SMN2 (0.53) | CHRNA7GAARAD52 | |
| SCHEMBL15685762 | 0.81 | CHRNA7 (0.57) | CHRNA7DRD2HTR7GAARAD52 | |
| SCHEMBL2377662 | 0.74 | CHRNA7 (0.56) | CHRNA7DRD2HTR1AHTR7GAA | |
| SCHEMBL1599712 | 0.73 | DRD2 (0.77) | CHRNA7DRD2HTR7GAARAD52 | |
| SCHEMBL10294634 | 0.73 | KCNH2 (0.69) | CHRNA7 | |
| SCHEMBL4577571 | 0.71 | CHRNA7 (0.56) | CHRNA7DRD2GAARAD52 | |
| SCHEMBL10819408 | 0.71 | KCNH2 (0.71) | CHRNA7DRD2HTR7GAARAD52 | |
| SCHEMBL1126080 | 0.71 | GAA (0.66) | CHRNA7DRD2HTR1AGAARAD52 | |
| SCHEMBL30647354 | 0.71 | GAA (0.66) | CHRNA7DRD2HTR1AGAARAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| CN-101501035-B | Pyrimidine derivatives as PI3K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD | 2013-01-23 | — | — | CN | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| CN-101501035-A | Pyrimidine derivatives as P13K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | CHRNA7 4804/4885DRD2 3654/4885HTR1A 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.